20 results about "Multiple tumors" patented technology

The invention discloses a brain glioma classification method and device based on multi-mode MRI, and relates to the technical field of image processing. According to the method, multiple tumor sub-regions of the brain glioma are acquired based on a to-be-processed multi-modal MR image, multiple local ROIs are extracted based on the multiple tumor sub-regions, and then the sub-type of the brain glioma is determined based on the multiple local ROIs and a global ROI. The subtype can be determined through the multi-modal MR image, so that on one hand, non-invasive identification of the subtype is realized, and bleeding and infection risks caused by identification of the subtype are avoided; and on the other hand, the classification accuracy can be improved by utilizing complementary information between different modal images and a boundary form between different tumor sub-regions. Besides, through the fine structure features of each tumor sub-region reserved from a plurality of visual angles by the plurality of local ROIs, and in combination with the spatial distribution context information of the whole brain glioma provided by the global ROI, a better balance between the processing precision and the calculation efficiency can be realized.

This invention provides a dual-modal composite tumor treatment system, belonging to the medical field, which solves the problem of inconvenient tumor examination due to the lack of routine tumor examinations. It includes a feature extraction module, a model construction module, a treatment determination module, and a real-time monitoring module. The feature extraction module extracts the physical characteristics of multiple tumor patients to obtain the frequency ranges of chest pain, cough, and chest tightness. The model construction module constructs a preliminary tumor identification model for each tumor patient. The real-time monitoring module monitors the physical characteristics of the examiner in real time to obtain the real-time frequency of chest pain, cough, and chest tightness. The treatment determination module makes a preliminary determination of the examiner's tumor condition. This invention achieves routine tumor examination based on a dual-modal approach.

The application discloses a traditional Chinese medicine gecko miRNA and application thereof. The application screens a traditional Chinese medicine gecko miRNA with potential anti-tumor effect by mining the miRNA from the traditional Chinese medicine gecko, and names the miRNA as gek-miR-2862, and the nucleotide sequence of the miRNA is shown as SEQ ID NO. 1. Research results show that the gek-miR-2862 can regulate multiple tumor-related signal pathways and inhibit liver cancer cell proliferation. Therefore, the traditional Chinese medicine gecko miRNA provided by the application can become a biological preparation for treating tumors and has potential drug development value, and provides a new solution for tumor treatment.

The application provides a boundary-aware three-dimensional MRI tumor segmentation method and a tumor diagnosis device. The method comprises: acquiring three-dimensional MRIs of multiple tumor patients as a tumor dataset, the three-dimensional MRIs comprising gadolinium-enhanced T1 SC slices; performing tumor segmentation on the three-dimensional MRIs in the tumor dataset as input of a first segmentation model to obtain a class label of the tumor in the three-dimensional MRI; wherein the first segmentation model is a model based on a convolutional neural network (CNN), the first segmentation model comprises a first model branch and a second model branch, the first model branch is used for predicting the class label, and the second model branch is used for predicting a surface distance field of the tumor based on boundary awareness, the surface distance field is used for describing the nearest distance of each voxel in the three-dimensional MRI to the surface of the tumor, and the training and optimization of the first segmentation model are based on the training and optimization of the first model branch and the second model branch.

The utility model discloses a kind of kits for multiple tumor marker detection, it is related to medical instrument technical field, including box and sample liquid preparation component, the box one end is equipped with receiving groove, the sample liquid preparation component is set in receiving groove inside, the sample liquid preparation component includes the needle cylinder being set to outside, needle cylinder inside is filled with blood sample diluent in advance.This application provides a kind of kits for multiple tumor marker detection, the blood sample of examinee is injected by needle cylinder one side middle part injection port using syringe, and mixed with the blood sample diluent filled in advance in needle cylinder, operator handheld needle cylinder and through the cooperation of rotating shaft sleeve and receiving groove side wall connecting port, swing needle cylinder so that blood sample and diluent are mixed uniformly, squeeze needle handle again, and sample liquid flows to detection area through distribution flow channel, the sample liquid preparation component is integrated in the side of box in this application, it is convenient for user to prepare blood sample quickly, and it is more practical.

This invention provides a method for analyzing tumor-specific gene mutations in subjects with multiple tumors, based on gene mutation information identified by ctDNA testing. [Solution] A step of obtaining first gene mutation information identified by ctDNA testing of the subject, second gene mutation information output by analyzing images of a first target area in the subject, and third gene mutation information output by analyzing images of a second target area in the subject that is different from the first target area, and A step of determining whether a tumor-specific gene mutation included in the first gene mutation information is related to a gene mutation in the first target site for imaging included in the second gene mutation information, or a gene mutation in the second target site for imaging included in the third gene mutation information. A method for analyzing gene mutations, comprising the following:

This invention discloses a tumor marker detection system based on an antibody-modified gold nanoparticle periodic linear array, belonging to the field of biomolecular detection. In this invention, a primary antibody is modified onto gold nanowires, and a nanolabel of antibody molecules modified onto gold nanoparticles is prepared as a detection tag (secondary antibody) for tumor markers. A test solution mixed with the secondary antibody is drop-coated onto the structure, and after a sufficient reaction time, the entire structure is rinsed. When light is incident perpendicularly on the gold nanowire array, surface plasmon resonance (SPR) occurs. The tumor markers (antigens) present in the solution are specifically adsorbed with the primary and secondary antibodies, forming a double-antibody sandwich structure, which changes the macroscopic color of the structure. By observing whether the color changes in different regions of the nanowire array after detection, the presence of tumor markers in the test solution can be determined. This invention's system can simultaneously detect multiple tumor markers and features short detection time, small size, low cost, high sensitivity, and ease of outdoor observation.

The application belongs to the field of intelligent medical treatment, and particularly relates to a bladder tumor image segmentation method, device, medium and program product. The method comprises the following steps: S101, acquiring an image of a bladder tumor patient; S102, inputting the image into a 2D U-Net for tumor segmentation to obtain a 2D segmentation result; S103, based on the 2D segmentation result, traversing the shape of the tumor, if the current tumor shape is regular, inputting the image into a 3D U-Net for tumor segmentation to obtain a 3D segmentation result, and taking the segmentation result of the current tumor in the 3D segmentation result; if the tumor shape is irregular, taking the segmentation result of the current tumor in the 2D segmentation result, and after the traversal is completed, merging and outputting the segmentation results of multiple tumors. The application can optimize the segmentation performance by using the complementary advantages of the 2D-3D method, and obtain better segmentation results.

This invention relates to a method for using an antibody-drug conjugate to treat cancer. Specifically, the invention provides a method for using an antibody-drug conjugate, its pharmaceutically acceptable salt, stereoisomer, or metabolite, or a solvate thereof, to treat cancer, and the use of said antibody-drug conjugate in the preparation of medicaments for the prevention and / or treatment of cancer. The method has improved safety and has demonstrated promising antitumor activity in multiple tumor types, meeting medical needs.

This invention discloses an electrochemiluminescence microfluidic chip for the detection of multiple tumor markers, relating to the field of biodetection technology. It includes a substrate and a microfluidic channel system, an electrochemiluminescence detection unit, and a signal acquisition interface integrated on the substrate. The microfluidic channel system includes a sample inlet, a shunt structure, multiple parallel and equally spaced detection channels, and a waste liquid pool connected in sequence. The shunt structure includes a main channel and multiple branch channels integrally formed with the main channel. In this invention, the microfluidic channel system, the electrochemiluminescence detection unit, and the signal acquisition interface are integrated on the same substrate, achieving an integrated design for sample transmission, reaction, detection, and signal export. Compared to traditional distributed detection technologies, this significantly simplifies the detection operation steps, reduces the professional skills required of operators, and shortens the detection cycle, meeting the needs of rapid clinical diagnosis.

A method of delivering tumor treating electric fields to a patient after tumor remission using predictive data in a preventive therapy, which includes the steps of: reviewing a scan of the body; identifying remissive tumor-filled areas on the scan; determining a spatial relationship between remissive tumor-filled areas and predicted locations of tumors; arranging an array of insulated electrode elements on the body, the array of electrode elements being coupled to an electric field generator, a control device configured to send a signal to the generator causing the generator to deliver tumor-preventative electric fields to the electrode elements; determining at least two subarray firing configurations for the array of electrode elements for targeting the remissive tumor-filled areas, the subarray firing configurations depending at least in part upon the spatial relationship between the two remissive tumor-filled areas; and delivering the tumor-treating fields to the remissive tumor-filled areas using the subarray firing configurations.

The invention discloses application of artesunate in preparation of a PRMT1 inhibitor and / or an alpha-ketoglutaric acid supplement, and relates to the technical field of biological medicines. It is found through experiments that artesunate can target and inhibit the activity of arginine methyltransferase of PRMT1, inhibit methylation modification of downstream molecules IDH2 of PRMT1 and reduce expression of the downstream molecules IDH2, and then mitochondrial metabolic disorder in cancer cells is induced, including accumulation of various metabolites such as alpha-ketoglutaric acid. Therefore, a new application of artesunate is provided, and artesunate is used for preparing a PRMT1 inhibitor and / or an alpha-KG supplement. In addition, it is verified that artesunate can significantly inhibit tumor growth of multiple tumor-bearing mice and promote anti-tumor immunity, and artesunate can be used as a PRMT1 inhibitor and / or an alpha-KG supplement to prepare anti-tumor immunotherapy drugs.

This application relates to a method, apparatus, computer device, readable storage medium, and computer program product for processing microscope parameters. The method includes: acquiring input microscope parameters in response to a microscope parameter input operation triggered in a displayed microscope parameter input interface; and displaying a report result display interface in response to a microscope parameter calculation operation triggered in the microscope parameter input interface. The report result display interface includes report results for the number of target fields of view corresponding to multiple different types of tumors. The number of target fields of view is the number of nuclear divisions required to observe each type of tumor within the field of view of a target microscope, based on diagnostic criteria for each type of tumor. The target microscope is the microscope corresponding to the microscope parameters. This method can improve the conversion efficiency between microscope field of view and multiple tumor diagnostic criteria.

The application discloses a prediction model for simultaneously detecting multiple tumors and performing tissue tracing as well as a training method and application thereof, and relates to the technical field of biological medicine. It is found that nucleosome distribution, fragment size distribution, terminal sequence distribution, genomic instability, gene expression prediction and somatic copy number variation can be used as markers to identify whether a sample to be detected contains any one or more of liver cancer, intestinal cancer, esophageal cancer, pancreatic cancer, lung cancer, gastric cancer, ovarian cancer and nasopharyngeal cancer, and to perform tissue tracing. The application has the advantages of high detection sensitivity, good specificity, high tissue tracing accuracy and low detection cost.

The present disclosure describes a machine learning (ML) framework including a graph convolutional neural network (GCN) for identifying gene expression features associated with cancer driven events. The model is trained to identify the TP53 mutation status of a cancer sample from gene expression using a comprehensive selected gene interaction map structure. A quantitative score is generated to rank the severity of the drive events in each sample. By means of the method, an extremely high AUC result is achieved on unseen data of multiple tumor types. And the gene has strong correlation with protein functions. Based on the annotations established in the literature, a transcriptome feature (STAMP) model associated with the mutant protein can also predict driving events of a variety of important cancer gene / pathway combinations and a variety of tumor types. Therefore, the STAMP model can identify and quantify driving events, which can provide a new way for cancer patients to improve selection and priority ranking of targeted therapy.

Methods of treating cancer, including methods that administer to a patient an agent that may be an inducer of cancer stem cell differentiation and mesenchymal to epithelial transition (MET) in multiple tumor cell lines in a 3D culture model that recapitulates clinically relevant tumor cell states in vitro. The differentiating activity of the agents in cancer stem cells may occur through over-activation, rather than inhibition, of the Notch pathway. Methods of screening agents, and pharmaceutical compositions.

Disclosed in the present invention are a dried blood spot tumor marker detection system, a kit and the use thereof. The system comprises the following modules: S1, a sample collection module, wherein the module is used for collecting a blood sample using a blood sample collection card to obtain a dried blood spot sample; S2, a tumor marker extraction module, wherein the module is used for extracting a tumor marker using an extraction buffer; specifically, the dried blood spot sample is placed into the extraction buffer and shaken, and the supernatant is collected to obtain a test solution; S3, a tumor marker detection module, wherein the module is used for detecting the tumor marker using a detection reagent; specifically, the test solution is brought into contact with the detection reagent, and detection is performed using a flow fluorescence analyzer to obtain a detected concentration; and S4, a data processing module, wherein the module is used for performing data processing on the detected concentration; specifically, the detected concentration is multiplied by a serum-to-dried blood spot correlation coefficient to obtain a final concentration. The system is particularly suitable for the quantitative analysis of multiple tumor markers in dried blood spots, with a high accuracy and a good repeatability of detection results.

The invention relates to a method of delivering a tumor treatment electric field to a patient's body. The method comprises scanning the patient's body to identify at least two tumor fill regions. The method further comprises determining a spatial relationship between the at least two tumor fill regions. The method further comprises arranging an array of insulated electrode elements on the patient's body. The method further comprises implementing at least two sub-array emission configurations of the array of insulated electrode elements at least partly in accordance with the spatial relationship between the at least two tumor fill regions to treat the at least two tumor fill regions such that each sub-array emission configuration treats a respective tumor fill region. The invention further relates to a method of configuring a tumor treatment field device and a tumor treatment field device comprising an array of insulated electrode elements coupled to a control device.

The invention belongs to the technical field of biological medicines, and particularly discloses a preparation method of an engineered tumor cell vesicle vaccine loaded with multiple antigen targeting DC cells. Wherein the engineered cell stable transfection strain of the targeting DC cell comprises a structural domain for recognizing a DC cell surface antigen and a transmembrane structural domain. The engineered vaccine disclosed by the invention can specifically recognize DC cells after entering a body, and meanwhile, various tumor-associated antigens contained in tumor cell vesicles carried by the engineered vaccine are delivered to the DC cells to promote the DC cells to uptake and present tumor antigens, so that T cells of the engineered vaccine are activated, and the anti-tumor capability of dendritic cells in a tumor microenvironment is enhanced; the infiltration of T cells in tumor tissues is further enhanced, so that the anti-tumor capability is enhanced.